Bringing the fundamentals into focus…
Bringing the fundamentals into focus…
DNA · against 588 other Healthcare companies listed in US-listed
Ranked #207 of 589 · scores higher than 65% of peers
Bars: peers in each 10-point band of the valuation score45 peers with a valuation score of 40–49, including DNA · Click a bar to see the companies
Its metrics sit close to the Healthcare norm.
| Metric | DNA | Peer median | Better than | Position among peers | Weight |
|---|---|---|---|---|---|
| Earnings yieldHigher is better · 577 reported | -47.0% | -4.3% | 10% | 30% | |
| EBITDA yieldHigher is better · 578 reported | -31.7% | -0.8% | 15% | 50% | |
| Free cash flow yieldHigher is better · 553 reported | -24.1% | -2.3% | 13% | 20% | |
| Book yieldHigher is better · 587 reported | 61.3% | 25.9% | 80% | Context only |
| Rank | Company | Market cap | Valuation | Overall |
|---|---|---|---|---|
| 1 | 256M USD | 98 | 80 | |
| 2 | 595M USD | 96 | 97 | |
| 2 | 433M USD | 96 | 81 | |
| 2 | 289M USD | 96 | 57 | |
| 2 | 810M USD | 96 | 69 | |
| 201 | 40.2B USD | 46 | 73 | |
| 201 | 11.4B USD | 46 | 64 | |
| 201 | 49.1B USD | 46 | 69 | |
| 207 | 1.9B USD | 45 | 68 | |
| 207 | 725M USD | 45 | 19 | |
| 207 | 5.3B USD | 45 | 50 | |
| 210 | 10.5B USD | 44 | 56 | |
| 210 | 5.7B USD | 44 | 38 | |
| 210 | 1.3B USD | 44 | 58 |
Scores are sector-relative percentiles from the latest snapshot, always calculated against the whole sector: narrowing the comparison group changes who you compare with, not the scores. Missing metrics are left out and the remaining weights rescaled. How we score